Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A PET-CT study on neuroinflammation in Huntington's disease patients participating in a randomized trial with laquinimod.
Roussakis AA, Gennaro M, Gordon MF, Reilmann R, Borowsky B, Rynkowski G, Lao-Kaim NP, Papoutsou Z, Savola JM, Hayden MR, Owen DR, Kalk N, Lingford-Hughes A, Gunn RN, Searle G, Tabrizi SJ, Piccini P. Roussakis AA, et al. Among authors: borowsky b. Brain Commun. 2023 Apr 3;5(2):fcad084. doi: 10.1093/braincomms/fcad084. eCollection 2023. Brain Commun. 2023. PMID: 37020532 Free PMC article.
Association of CAG Repeats With Long-term Progression in Huntington Disease.
Langbehn DR, Stout JC, Gregory S, Mills JA, Durr A, Leavitt BR, Roos RAC, Long JD, Owen G, Johnson HJ, Borowsky B, Craufurd D, Reilmann R, Landwehrmeyer GB, Scahill RI, Tabrizi SJ; TRACK-HD and Track-On HD Groups. Langbehn DR, et al. Among authors: borowsky b. JAMA Neurol. 2019 Nov 1;76(11):1375-1385. doi: 10.1001/jamaneurol.2019.2368. JAMA Neurol. 2019. PMID: 31403680 Free PMC article.
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC; TRACK-HD investigators. Tabrizi SJ, et al. Among authors: borowsky b. Lancet Neurol. 2009 Sep;8(9):791-801. doi: 10.1016/S1474-4422(09)70170-X. Epub 2009 Jul 29. Lancet Neurol. 2009. PMID: 19646924 Free PMC article. Clinical Trial.
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR; TRACK-HD investigators. Tabrizi SJ, et al. Among authors: borowsky b. Lancet Neurol. 2012 Jan;11(1):42-53. doi: 10.1016/S1474-4422(11)70263-0. Epub 2011 Dec 2. Lancet Neurol. 2012. PMID: 22137354
Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease.
Orth M, Gregory S, Scahill RI, Mayer IS, Minkova L, Klöppel S, Seunarine KK, Boyd L, Borowsky B, Reilmann R, Bernhard Landwehrmeyer G, Leavitt BR, Roos RA, Durr A, Rees G, Rothwell JC, Langbehn D, Tabrizi SJ; TRACK-On Investigators. Orth M, et al. Among authors: borowsky b. Hum Brain Mapp. 2016 Dec;37(12):4615-4628. doi: 10.1002/hbm.23332. Epub 2016 Aug 1. Hum Brain Mapp. 2016. PMID: 27477323 Free PMC article.
Design optimization for clinical trials in early-stage manifest Huntington's disease.
Frost C, Mulick A, Scahill RI, Owen G, Aylward E, Leavitt BR, Durr A, Roos RAC, Borowsky B, Stout JC, Reilmann R, Langbehn DR, Tabrizi SJ, Sampaio C; TRACK-HD Investigators. Frost C, et al. Among authors: borowsky b. Mov Disord. 2017 Nov;32(11):1610-1619. doi: 10.1002/mds.27122. Epub 2017 Sep 14. Mov Disord. 2017. PMID: 28906031
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators. Reilmann R, et al. Among authors: borowsky b. Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15. Lancet Neurol. 2019. PMID: 30563778 Clinical Trial.
Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review.
Kinnunen KM, Schwarz AJ, Turner EC, Pustina D, Gantman EC, Gordon MF, Joules R, Mullin AP, Scahill RI, Georgiou-Karistianis N; Huntington's Disease Regulatory Science Consortium (HD-RSC). Kinnunen KM, et al. Front Neurol. 2021 Sep 21;12:712555. doi: 10.3389/fneur.2021.712555. eCollection 2021. Front Neurol. 2021. PMID: 34621236 Free PMC article. Review.
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR; TRACK-HD Investigators. Tabrizi SJ, et al. Among authors: borowsky b. Lancet Neurol. 2013 Jul;12(7):637-49. doi: 10.1016/S1474-4422(13)70088-7. Epub 2013 May 9. Lancet Neurol. 2013. PMID: 23664844
65 results